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ARTICLE
Supramammillary glutamate neurons are a key
node of the arousal system
Nigel P. Pedersen 1, Loris Ferrari2,3, Anne Venner 2,3, Joshua L. Wang 2, Stephen B.G. Abbott2,
Nina Vujovic3, Elda Arrigoni2,3, Clifford B. Saper2,3 & Patrick M. Fuller2,3
Basic and clinical observations suggest that the caudal hypothalamus comprises a key node
of the ascending arousal system, but the cell types underlying this are not fully understood.
Here we report that glutamate-releasing neurons of the supramammillary region (SuMvglut2)
produce sustained behavioral and EEG arousal when chemogenetically activated. This effect
is nearly abolished following selective genetic disruption of glutamate release from SuMvglut2
neurons. Inhibition of SuMvglut2 neurons decreases and fragments wake, also suppressing
theta and gamma frequency EEG activity. SuMvglut2 neurons include a subpopulation con-
taining both glutamate and GABA (SuMvgat/vglut2) and another also expressing nitric oxide
synthase (SuMNos1/Vglut2). Activation of SuMvgat/vglut2 neurons produces minimal wake and
optogenetic stimulation of SuMvgat/vglut2 terminals elicits monosynaptic release of both
glutamate and GABA onto dentate granule cells. Activation of SuMNos1/Vglut2 neurons
potently drives wakefulness, whereas inhibition reduces REM sleep theta activity. These
results identify SuMvglut2 neurons as a key node of the wake−sleep regulatory system.
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In the 1930s, von Economo
1 proposed that damage to
diencephalic-mesencephalic junction was responsible for
marked somnolence in patients with epidemic encephalitis
lethargica, and Ranson2 was able to reproduce this somnolence
with lesions of the caudal hypothalamus in monkeys. Supporting
this observation, Moruzzi and Magoun3 found that stimulation of
the caudal hypothalamic region could elicit wakefulness
and electrocortical low-voltage fast activity at a threshold
comparable to brainstem arousal sites, and at a lower threshold
than for the thalamus. This induced arousal was seen even
after destruction of the thalamus4, while caudal hypothalamic
lesions or inactivation resulted in marked and often prolonged
somnolence2, 3, 5–10. These experiments and similar
observations in humans1, 11–16 supported the existence
of a key node of the arousal system within the caudal
hypothalamus.
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While orexin neurons in the lateral hypothalamus and tuber-
omammillary histaminergic neurons both promote arousal,
lesions of these caudal hypothalamic cell groups have not been
found to cause the level of hypersomnolence produced by larger
posterior hypothalamic lesions17, 18. Based upon its anatomical
connectivity and cellular composition, we hypothesized that the
supramammillary nucleus (SuM), a region lying just dorsal to the
mammillary body in the caudal hypothalamus, might comprise a
key site for wake-promotion. The SuM provides extensive
innervation of the cerebral cortex19, wake-promoting basal fore-
brain20–25, and the hippocampus19, 20, 26–28, 33. Neurons in the
SuM are known to play a role in driving hippocampal theta
rhythm, displaying theta band ﬁeld potentials in freely moving
rats29, and unit discharges that correlate with this theta mod-
ulation30, 31. Previous work has examined the relationship of SuM
activity to hippocampal local ﬁeld potentials and learning27, 32–34,
and suggested a role for SuM neurons in REM sleep13, 35, but the
SuM has not been studied at all in relation to wakefulness, nor
with respect to the possibly distinct roles of SuM subpopulations
in REM sleep and wakefulness. Whereas most neurons in the
SuM region are glutamatergic36, 37, there is anatomical evidence
that some of these neurons may contain other neuromodula-
tors23, 38–41 including a subpopulation of SuM neurons targeting
the hippocampus that contain anatomical markers of both GABA
and glutamate release42, 43. Here we used a combination of tar-
geted genetic and viral vector technologies in behaving mice to
determine whether SuM neurons contribute to electrocortical and
behavioral arousal. We then employed in vitro optogenetics and
application of a novel non-parametric mapping technique to
delimit and characterize three distinct cell populations in the SuM
region, each of which differentially contribute to cortical and
hippocampal activation and behavioral wake. Our results show
that SuMVglut2 neurons are necessary for normal wakefulness,
with activation potently promoting theta and gamma EEG
activity and wakefulness. SuMNos1/Vglut2 neurons can promote
wake when activated and are also necessary for normal REM
theta activity. SuMVgat/Vglut2 neurons provide dense innervation
of the dentate gyrus and CA2, monosynaptically releasing both
GABA and glutamate on to the proximal dendrites of dentate
granule cells, but only minimally affecting sleep−wake and,
Fig. 1 Caudal hypothalamic activation potently drives wakefulness. a Cartoon showing AAV-FLEX-hM3Dq-mCherry virus recombining in vglut2 neurons in
the presence of Cre. b Example injection site showing diaminobenzadine (DAB) labeling of mCherry (red−brown staining, red outline) and nickel/cobalt
enhanced DAB (black) labeling of cFos in nuclei (see also inset, scale bar 10 µm) of neurons activated by CNO (main panel scale bar 500 µm, SuM shown
in black outline). c, d Hypnograms after vehicle and CNO showing prolonged wakefulness after activation of glutamate neurons (W–wake, N–NREM sleep,
R–REM sleep; gray= dark period). e, f Compressed spectral array (CSA) based on fast Fourier transform (FFT) after vehicle and CNO (0–100 Hz, black bar
shows the dark period, short white bars represent 20min and are spaced 1 h apart; time periods in blue and red boxes for NPM005 in c and d are shown in
e and f), with prominent theta activity after CNO. g Group data (mean± SEM) showing signiﬁcantly higher wakefulness for nine hours after CNO (2-way
repeated measures ANOVA for treatment p< 0.0001, Bonferroni ***p< 0.001; *p< 0.05). h Waking EEG (mean± SEM) shows increased high theta
(HTheta, 7−13 Hz, p= 0.0148), gamma (30−120 Hz, p= 0.0005), and decreased low theta component of the FFT power spectrum (LTheta, 4−7 Hz, p=
0.0027). i Cortical and hippocampal (inset) EEG FFT spectra (log frequency, arbitrary units (AU)) showing prominent hippocampal ~ 9 Hz activity. j Raw
wake EEG and EMG data with CSA (0−30Hz) over 5 s for vehicle, and k. CNO, with prominent 9−10 Hz activity visible in the CSA in the latter case
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Fig. 2 Wake-promoting neurons are within the SuM region. a Smaller injection sites (red outline) showing prolonged wakefulness (hours of wake after
CNO at bottom left of each panel) was highest with involvement of the whole SuM (scale bar 500 µm). b Plot of all injection sites as a ‘heat map’ of
injection overlap (n= 21, dark red minimal overlap (1 case), white maximal (18 cases)). c Non-parametric permutation analysis shows that the area of
transduction correlated with the longest duration of wakefulness after CNO is the caudal hypothalamus, most notably the SuM (yellow area false discovery
rate< 0.01). MM–medial mammillary, LM–lateral mammillary, and FF–ﬁelds of Forel
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interestingly, do not as potently promote theta EEG activity
despite targeting the hippocampal network. In concert with these
observations and the described anatomical connectivity of the
SuM, these results suggest that SuMVglut2 neurons comprise a key
nod of the sleep−wake regulatory system that is positioned to
control both the hippocampal system and arousal.
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Results
SuMvglut2 neurons drive wakefulness. In our ﬁrst experiment,
we tested whether glutamate neurons of the caudal hypothalamus
drive wakefulness. In order to selectively activate caudal
hypothalamic glutamate neurons, including SuM glutamate
(SuMvglut2) neurons, we ﬁrst made large stereotaxic injections of
an adeno-associated viral vector (AAV) that conditionally
expressed an excitatory modiﬁed human G-protein coupled
muscarinic receptor (hM3Dq)44, 45 fused to the mCherry ﬂuor-
escent protein (AAV-hM3Dq), into the caudal hypothalamus of
vglut2-IRES-Cre mice (Fig. 1a). Functional transduction of the
SuM neurons was shown by administration of the hM3Dq ligand
clozapine-n-oxide (CNO, 0.3 mg/kg in 10 µl/g normal saline
vehicle i.p.), which drove cFos expression in the transduced
neurons (Fig. 1b, upper right). Administration of CNO after
injection of AAV-hM3Dq in non-Cre-expressing control litter-
mates, or injections of vehicle (Fig. 1c) after injection of AAV-
hM3Dq in Cre-expressing mice was without effect on sleep−wake
or cFos expression. In contrast, CNO-driven activation of
hM3Dq-expressing SuMvglut2 neurons potently promoted con-
tinual wakefulness, in some cases for periods as long as 12 h,
during the animals’ normal sleep period (Fig. 1d; administration
3 h after lights-on (Zeitgeber (ZT) 3, 10 AM; Latency to sleep:
saline 22± 4 (SEM), CNO 534± 54 min, paired t-test,
p= 0.000014, n= 9, see group data Fig. 1g). In these mice, CNO
also caused a signiﬁcant increase in higher range theta activity
(HTheta 7–13 Hz, paired t-test with Bonferroni correction,
p= 0.0148, n= 5, spectral peak at about 9 Hz), and decrease in
lower frequency theta EEG activity (low range theta (LTheta)
4–7 Hz, p= 0.0027) (Fig. 1e, f, h, i) with a signiﬁcant increase in
gamma frequency EEG activity (gamma 30–120 Hz, p= 0.0005).
Bipolar recording from the hippocampus (n= 6) revealed similar
EEG spectral changes, conﬁrming concomitant hippocampal
activity with a spectral peak at 8.5–9 Hz (Fig. 1i upper right).
Importantly, the repertoire of behavior after CNO in these mice
was normal (Supplementary Movie 1), and the amount or speed
of locomotor activity did not account for theta activity (mice were
often stationary, e.g., see raw data in Fig. 1j, k with periods of low
EMG in both examples, but increased theta power (red) in
Fig. 1k; Supplementary Movie 1). Given the known role of the
SuM in the genesis of the theta activity, we hypothesized that the
wake-promoting cell group was either identical with or adjacent
to the SuM neurons that promote theta.
We next scattered small injections of AAV-hM3Dq throughout
the SuM and adjacent regions to better understand the precise
location of the wake-promoting neurons (n= 15). We studied
each injection site in detail, noting which nuclei were wholly or
partially involved in the injection site and their degree of
transduction. We noted that small injection sites ﬂanking the
SuM were associated with minimal wakefulness after CNO
injection, while those involving the whole of the SuM were
associated with the most prolonged wakefulness (see examples,
Fig. 2a). To analyze these data in an objective fashion, we made a
three dimensional (3D) map of the injection site, plotted as 30 µm
cubic voxels on to a template derived from a high resolution
mouse brain MRI scan (Fig. 2b). We then used a non-parametric
permutation test of voxels containing transduced neurons and
correlated this with the duration of wakefulness resulting from
SuM activation (Fig. 2c, n= 21; Methods section). This produced
an anatomical z-score, revealing that the combination of voxels
that was statistically associated with increased wakefulness
corresponds best to the SuM region (false discovery rate< 0.01
and corresponding to a z≥ 3.216, n= 21). Conversely, caudal
hypothalamic regions immediately surrounding the SuM region
did not signiﬁcantly contribute to prolonged wakefulness.
Involvement of somewhat further cell groups such as the lateral
and perifornical regions may have accounted for the most
prolonged duration of wakefulness with the largest injection sites,
given the known wake-promoting effect of orexin neurons that
also express vglut2 in that region. Smaller injections with
transduction constrained within the SuM resulted in just over
5 h of wakefulness (saline 29± 5 min versus CNO 310± 40 min,
n= 6, p= 0.0012), indicating that this caudal hypothalamic cell
group independently promotes wakefulness.
SuM actions depend on glutamate. Given the presence of
other mediators such as nitric oxide, GABA, and several pep-
tides23, 38–43 in the SuM, we next sought to determine whether
glutamate is necessary for the wake-promoting effect of SuM
neuronal activation. To test this hypothesis, and whether the
action of unopposed GABA release might decrease wakefulness,
we placed stereotaxic injections of both AAV-Cre and a condi-
tional AAV-hM3Dq into the SuM region of vglut2lox/lox mice, to
concurrently disrupt synaptic glutamate release and express
hM3Dq in transduced neurons (Fig. 3a). Because only neurons
that had been transduced with the AAV-Cre (and therefore
deleted the vglut2 gene) would also express the hM3Dq, CNO
would only drive neurons that lacked functional VGLUT2 pro-
tein. Histologically, there was effective co-expression of hM3Dq
and cFos after CNO over a large part of the SuM (Fig. 3b), with
correlated loss of vglut2 in situ hybridization signal (compare
Fig. 3c, d). Activation of these SuM neurons resulted in a brief
period of wakefulness that was not statistically signiﬁcant from
vehicle injection (vehicle 21± 4 (SE) min versus CNO 49±
12 min, p= 0.06, n= 6, Fig. 3e−h, summary data Fig. 3i), and was
far shorter than comparable activations of neurons without vglut2
deletion (Fig. 1c, d), suggesting that glutamate release from SuM
neurons is required for the bulk of the wake-promoting effects of
SuM activation. Furthermore, EEG spectral changes associated
with activation of SuM vglut2-only neurons were abolished, with
no changes in individual spectral bands in any state (p> 0.99 in
wake, n= 6, see wake spectra Fig. 3g, h, j).
Fig. 3 Wake-promotion after SuM activation depends on glutamate. a Cartoon showing that after co-injection of AAV-FLEX-hM3Dq-mCherry and AAV-
Cre in a vglut2ﬂox mouse, that vglut2 is disrupted in neurons expressing Cre, with Cre positive neurons also able to drive hM3Dq expression. Thus, the
only neurons activated by CNO are neurons that lack glutamate release. b mCherry-like immunoreactivity and cFos expression after CNO administration
(left) showing where hM3Dq was transduced, and cFos expression consistent with cellular activation after CNO. c Normal expression of vglut2,
revealed by in situ hybridization, and d in situ hybridization showing the loss of vglut2-expression in the injection site in the same mouse shown in b (area
with near-complete signal loss shown in yellow, area with deletion in some neurons is outlined in orange). e, f Hypnograms of two mice showing marked
attenuation of wake-promoting effects of SuM activation, consistent with substantial dependence on glutamate release. g, h CSA showing the effect of
vehicle and the near-absent effect of activation with CNO in the period shown by the blue and red boxes in c and d, respectively (0−100 Hz, black bar
shows the dark period, short white bars represent 20min and are spaced 1 h apart). i Pooled data (mean± SEM in 1 h bins, n= 6) after saline and
CNO administration, with post hoc comparisons showing that more of only the ﬁrst hour is spent awake after CNO (Bonferroni corrected comparison
for 1 h p= 0.0153, all other hours p> 0.99). j Spectral changes associated with SuM activation are also abolished (wake from 6 h after injection shown,
mean± SEM, n= 6)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01004-6 ARTICLE
NATURE COMMUNICATIONS |8:  1405 |DOI: 10.1038/s41467-017-01004-6 |www.nature.com/naturecommunications 5
Chronic vglut2 deletion in the SuM had little effect on amounts
of wake, REM, and NREM sleep, all of which remained within
normal limits for mice (wake 45.2± 2.5%, NREM 48.4± 2.4%,
REM 6.4± 0.2%, n= 6). However, like the ibotenic acid lesions of
the rat SuM by Renouard et al.35, the deletions in these
experiments never covered the entirety of the SuM, and because
of the time it took for the full deletion to occur and for the
animals to recover, there was ample time for compensation. We
therefore tested the effect of acute inhibition of the SuMVglut2
cells on wakefulness.
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SuMvglut2 neuronal inhibition causes somnolence. To examine
the effect of acute inhibition the SuMVglut2 neurons, we used a
conditionally expressed modiﬁed inhibitory human muscarinic 4
receptor (hM4Di)44, 45. We made large injections of an AAV-
FLEX-hM4Di-mCherry (AAV-hM4Di) vector in the posterior
hypothalamus of vglut2-IRES-Cre mice (Fig. 4a), deliberately
including as much as possible of the SuMvglut2 cell population
(Fig. 4b). We validated that CNO was able to inhibit transduced
neurons by recording SuM neurons in vitro in the cell attached
mode. CNO (5 µM) reduced the ﬁring frequency of SuMvglut2
neurons that express hM4Di (ﬁring frequency in control 0.89±
0.27 Hz, CNO 0.09± 0.05 Hz; p= 0.02 paired t-test,
n= 6) (Fig. 4c−g). CNO had no effect in SuMvglut2 neurons that
only express mCherry (ﬁring frequency in control 1.2± 0.6 Hz,
CNO 1.35± 0.65 Hz; p= 0.42, paired t-test, n= 5) (Fig. 4h−j).
In freely behaving mice, increased sleep and fragmentation
of wakefulness and sleep were present after CNO injection
(Fig. 4k−n). Increased NREM sleep was signiﬁcant, elevated by
about 20% over the 6 h following CNO administration (injection at
ZT12, typical time of maximal wakefulness, saline 33.8± 2.80%
(SEM) versus CNO 41.95± 1.49%, 2-way ANOVA, p= 0.0199,
n= 6, Fig. 4o). This was at the expense of both wakefulness and
REM sleep, although neither reduction reached statistical signiﬁ-
cance (2-way ANOVA by state; wake—62.4± 2.85 versus 55.8±
1.94%, p= 0.0659, n= 6; REM −3.31± 0.34 versus 2.31± 0.72%,
p= 0.2614). There was an increased number of sleep bouts in the
six hours following injection, as well as a reduction in the maximal
time for which wakefulness was maintained (saline 24.5± 2.56
(SEM) versus 37.3± 2.90 bouts, paired t-test, p= 0.0194, n= 6,
Fig. 4p), with the longest wake bouts after saline being signiﬁcantly
longer than after CNO (44.5± 7.83 versus 28.2± 4.98min,
p= 0.0152, n= 6, Fig. 4q). The spectral power changes were
inverse to those of activation, i.e., we saw a signiﬁcant decrease in
high frequency theta and gamma power during wakefulness
(HTheta p< 0.0001, and Gamma p= 0.0472, n= 5, Fig. 4r). There
was also an increase in the power of low-frequency (4−7Hz), but
not high-frequency (7−13 Hz) theta during REM sleep (p< 0.0001,
n= 5, Fig. 4s), with no effect on other REM spectral bands
(p> than 0.16 for all bands), nor in the power spectrum of NREM
sleep (p= 0.38 to> 0.99 for all bands, Fig. 4t). These changes in
power spectrum and sleep architecture are consistent with
sleepiness during the wake state and the inability to sustain longer
bouts of wakefulness, but normal NREM sleep.
SuMvgat/vglut2 neurons. GABAergic neurons surround the
mammillothalamic tract as it penetrates the SuM37, 43, and spread
medially and laterally in the more posterior SuM. The terminals
of these neurons in the hippocampus have been reported to
contain markers of both GABA and glutamate release42, 43. Given
that these neurons are within our region of interest, we sought to
understand if they were also capable of driving cortical and
hippocampal activation and/or behavioral arousal. We ﬁrst
sought to verify the exact location of the GABA/glutamate neu-
rons in the SuM. We performed in situ hybridization for vglut2
mRNA in a vgat-IRES-Cre reporter mouse (L10 reporter line, see
Methods), revealing Vglut2 expression in all of the GABAergic
neurons surrounding the mammillothalamic tract in the SuM—
thus neurons in the SuM are of either SuMvglut2 or SuMvgat/vglut2
phenotype (Fig. 5a). The latter neurons are larger than the
adjacent ones expressing only vglut2 (20.54± 0.64 (SEM) µm
longest axis of soma, versus 13.93± 0.50 µm, unpaired t-test, p<
0.0001, n= 12,12), and correspond with what has been termed
the grandicellular ﬁeld (SuMg)40, forming a clear subset of larger
neurons in the SuM (Fig. 5b). There were no examples noted of
neurons that were only vgat positive within the SuM.
To determine whether these neurons co-release both neuro-
transmitters, we conditionally transduced channelrhodopsin-2
(ChR2) in the SuM of vgat-IRES-Cre mice (SuMvgat; Fig. 5c), then
made whole-cell recordings from dentate granule cells in
hippocampal brain slices (Fig. 5d). Photostimulation of Vgat
positive axons and terminals originating from the SuM (as shown
in the cartoon in Fig. 3d) evoked fast postsynaptic currents in
granule cells (15/18 neurons). Application of bicuculline or
DNQX reduced the amplitude of, but did not eliminate, photo-
evoked postsynaptic currents. The combination of bicuculline and
DNQX completely blocked postsynaptic responses, suggesting
mediation by release of both GABA and glutamate, respectively
activating GABA-A and AMPA receptors (Fig. 5e). Selective
blockade with these two antagonists revealed that GABA-A-
mediated postsynaptic currents had typical slower kinetics than
AMPA-mediated currents46 (Fig. 5f; decay time constants: 34.57
± 5.99 ms for the GABA-A-mediated current and 5.15± 1.06 ms
for the AMPA-mediated currents, ﬁtting with a single exponen-
tial; n= 3). Reversal potentials were −49.74± 3.65 mV (SEM) and
+11.94± 2.02 mV (n= 4 neurons from four brain slices from four
mice; p< 0.001, paired t-test), compatible with GABA-A-
mediated chloride and AMPA-mediated sodium currents,
respectively (Fig. 5g, h). Importantly, both the AMPA-mediated
and the GABA-A-mediated photo-evoked postsynaptic currents
had a short onset delay characteristic of photostimulation-evoked
release (GABA-A-mediated: 5.04± 0.37 ms and AMPA-
mediated: 4.33± 0.23 ms, n= 8, 9 neurons (from 3 vglut2-Cre
and 5 vgat-Cre mice, respectively), p= 0.002, paired t-test)
supporting monosynaptic release of both GABA and glutamate
from SuMvgat/Vglut2 terminals onto dentate granule cells (Fig. 5i,
j). Overall, photostimulation of the SuMvgat/Vglut2→DG pathway
evoked GABA-A-mediated and AMPA-mediated synaptic
responses in a large proportion of dentate granule cells (82%)
whereas it evoked solely GABA-A-mediated or AMPA-mediated
responses in only 9 and 9% of granule cells (n= 18), respectively.
We also conditionally expressed ChR2 in SuMvglut2 neurons, with
Fig. 4 Inhibition of the SuM results in somnolence and wake fragmentation. a Cartoon showing AAV-FLEX-hM4Di-mCherry recombining in vglut2 neurons
that express Cre. b Conditional transduction of inhibitory hM4Di in vglut2-IRES-Cre mice (red−brown staining outlined in red; scale bar 500 µm). c−g CNO
(5 µM) inhibits the ﬁring of SuMvglut2 neurons that express hM4Di-mCherry (c current-clamp recordings; d cell attached recordings; e−g expanded traces
of the outlined region from d, show ﬁring in control, during CNO application and in washout). h−j CNO (5 µM) has no effect on the ﬁring of SuMvglut2
neurons that only express mCherry (h; ﬁring frequency, 1-min bin, red arrows indicate the 1-min bins represented in i, j; i, j cell attached recordings of the
neuron in h). k, l Hypnograms from two mice over 12 h after vehicle and CNO, showing increased sleep and fragmentation of sleep and wakefulness after
inhibition of the SuM. m, n CSA after vehicle and CNO from the periods shown by the blue and red boxes, respectively, in c and d (0−100 Hz, black bar
shows the dark period, short white bars represent 20min and are spaced 1 h apart). o There is increased overall NREM sleep in the 6 h after CNO
administration (~20%; 2-way ANOVA for 6-hourly bins between vehicle and CNO, graph with mean± SEM, p= 0.0199), p wake-sleep fragmentation with
an increase in sleep bouts over the 6 h after CNO when compared with vehicle (paired t-test, mean± SEM, p= 0.0194). q The length of the longest
episode of wakefulness in the same time period was also signiﬁcantly reduced (paired t-test, mean± SEM, p= 0.0152). r Power spectrum (band mean±
SEM) with a signiﬁcant suppression of waking high theta activity (2-way repeated measures ANOVA, Bonferroni ***p< 0.0001) and gamma activity (*p=
0.0472), and s an unexpected increase in low theta power during REM sleep (***p< 0.0001), with t no change in the NREM spectrum
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photostimulation of terminals again evoking both GABA-A-
mediated and AMPA-mediated synaptic responses in 90% of
dentate granule cells, with AMPA responses alone in 10% of
granule cells (n= 9). This is consistent with previous studies
indicating that the SuM hippocampal projection arises from the
neurons adjacent to the mammillothalamic tract19. The mean
amplitude and mean onset delay of the photo-evoked glutamate-
mediated currents were –5.36± 1.06 pA and 4.55± 0.25 ms (Vh
= −70 mV) and for the GABA-A-mediated currents were +7.11±
0.89 pA and 5.84± 0.25 ms (Vh= 0 mV; n= 8), again consistent
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with a photic stimulation-evoked monosynaptic response (Fig. 5j).
Together, these results suggest that the SuM input to the dentate
gyrus predominantly originates from neurons that express both
vesicular transporters for glutamate and GABA (SuMvgat/vglut2)
and that these SuMvgat/vglut2 neurons co-release both transmitters
at their synaptic terminals.
We next examined whether SuMvgat/vglut2 neurons, represent-
ing about 15% of SuM neurons (see below), were wake-
promoting, by activating these neurons in vgat-IRES-Cre mice
after transduction with AAV-hM3Dq (Fig. 6a). Injection sites
covering the region of vgat expression in the SuM had a modest
but signiﬁcant effect on the duration of wakefulness following
CNO injection (saline 14± 3.6 (SE) min, versus CNO 92±
10 min, paired t-test, n= 4, p= 0.0027; Fig. 6c−g). Thus,
activation of these neurons was signiﬁcantly less wake-
promoting than activation of the entire population of SuMvglut2
neurons (duration of wakefulness, CNO in vgat-Cre mice 92±
10 min, vglut2-Cre mice 310± 40 min, n= 4, 6, p= 0.0028).
SuMNos1/Vglut2 neurons drive wake. As previously described in
cats and rats40, 41, the mouse SuM contains a subpopulation of
Nos1-containing neurons (Fig. 7a, b; see also Allen Mouse Brain
Atlas37). Given that cortical Nos1-expressing neurons have been
previously implicated in behavioral state control, albeit in the
regulation of slow-wave-sleep47, we sought to further understand
the anatomic distribution, cellular co-localization and physiology
of SuMNos1 neurons. We ﬁrst examined Nos1 immunoreactivity
in Vglut2-Cre-L10 reporter mice, and found Nos1 immunor-
eactive neurons to be scattered throughout the SuM, representing
about 15–20% of vglut2-positive neurons at all rostrocaudal levels
(Fig. 7a, b). We then used Nos1-IRES-Cre mice and stereotaxic
microinjection of AAV-hM3Dq into the SuM (Fig. 7c) to selec-
tively activate these neurons with CNO (see cFos in transduced
neurons, Fig. 7d). Activation of these neurons potently drove
sustained wakefulness (latency to sleep after saline 33± 4 (SEM)
min versus CNO 215± 27 min, n= 7, p= 0.0007, Fig. 7e, f), with
post hoc comparisons (Bonferroni corrected) showing a sig-
niﬁcantly elevated wakefulness for four hours after CNO injection
(Fig. 7i). While activation of SuMNos1/Vglut2 neurons resulted in
lesser wakefulness than activation of all SuMvglut2 neurons in the
cases with large injection sites (Fig. 1), the duration of wakeful-
ness was more than twice as long as after activating a similarly
numerous population of SuMvgat/Vglut2 neurons, and similar to
the amount of wakefulness driven by activation of SuMvglut2
neurons with smaller injection sites constrained within the SuM
(see above).
SuMNos1/Vglut2 neurons contribute to REM theta. To examine
the necessity of SuMNos1/Vglut2 neurons for normal wakefulness,
we made stereotaxic injections of AAV-hM4Di into the SuM of
Nos1-IRES-Cre mice (Fig. 8a), with transduction in the SuMNos1/
Vglut2 cellular ﬁeld (Fig. 8b). There was no signiﬁcant difference in
wake, NREM and REM sleep duration when mice were injected
with saline (vehicle) or CNO (0.3 or 0.9 mg/kg) (Fig. 8c−h), no
overall increase in sleep over the ﬁrst 6 h (p= 0.31, two-way
ANOVA for dose, n= 4, F (2, 6)= 1.423), nor fragmentation of
sleep-wake as measured by the number of wake bouts over the 6 h
after injection (p= 0.7588, n= 4, t= 0.3363, df= 3) nor changes
in the duration of longest wake in this period (saline 26 bouts±
5.1 versus CNO 0.9 mg/kg 23.75 bouts± 2.7, p= 0.6028, n= 4, t
= 0.5797, df= 3), which had all been noted after chemogenetic
inhibition of all SuM glutamate neurons (Fig. 4). However,
SuMNos1/Vglut2 neurons by our estimate account for no more
than 20% of the SuMVglut2 population, so inhibition of such a
small percentage of SuMVglut2 neurons may not have been suf-
ﬁcient to affect overall wake-sleep. On the other hand, power-
spectral analysis revealed a signiﬁcant decrease in high theta
power (7–13 Hz) during REM sleep (Fig. 8i) in these mice when
given CNO, but without changes in spectra during wakefulness
(p= 0.1744, two-way ANOVA, saline versus CNO 0.9 mg/kg, n=
4, F (1, 18)= 1.999; Bonferoni post hoc comparisons by band p>
0.9999 except for gamma p= 0.2335), suggesting a particularly
important role for SuMNos1/Vglut2 neurons in normal REM theta
activity (Fig. 8l).
Discussion
Prior studies in humans and animals have indicated that a key,
but hitherto uncharacterized, node of the arousal system resides
in the caudal hypothalamus1–16. Prior neuroanatomical tracing
and lesion studies were consistent with the SuM playing a role in
arousal, but the results of the present study for the ﬁrst time
demonstrate that the SuM is a major source of ascending arousal
tone. Furthermore, we demonstrate that release of glutamate from
SuM neurons is necessary for normal amounts of wake and EEG
spectral activity in the high-theta and gamma bands and for
consolidation of sleep−wake; and that acute inhibition of SuMv-
glut2 neurons results in an increase in NREM sleep and frag-
mentation of wakefulness.
With acute inhibition in mice, we also found no changes in
REM sleep amounts, although we did note an increase in low
frequency REM theta activity when all SuM neurons were
inhibited. SuMNos1/Vglut2 neurons were capable of promoting
wakefulness when activated, but inhibition of these neurons did
not alter sleep-wake or the waking power spectra, although it did
result in decreased theta activity in REM sleep. While chronic
cell-speciﬁc lesions of the SuM in rats have been reported to have
little effect on sleep-wake35, 48 including REM amounts, a recent
paper by Renouard et al.35, reported that SuM lesions reduced
7–10 Hz power in the EEG (high theta in the rat) during REM
sleep, and that dentate gyrus cFos expression during REM sleep
Fig. 5 SuM GABA/glutamate co-releasing neurons. a In situ hybridization for vglut2 (magenta) in a vgat-IRES-Cre/L10 reporter mouse (green, see
Methods section) reveals vglut2/vgat co-expression (white). b These neurons constitute a subpopulation of the larger neurons of the grandicellular SuM
(partially opaque). c Cartoon showing AAVx-FLEX-ChR2-mCherry recombining in the presence of Cre in either vglut2-Cre or vgat-Cre mice. d Cartoon of
optogenetically evoked stimulation of SuM terminals on dentate gyrus grandule cells, superimposed on a histological image showing dense anterograde
labeling (AAV-FLEX-GFP in vgat-Cre mouse) of SuM terminals in the dentate gyrus supragranular layer and CA2 (dark brown) with a light Nissl
counterstain (faint blue−purple; scale bar 500 µm). e Representative brain-slice voltage-clamp recording a dentate gyrus granule cell during
photostimulation of SuMvgat terminals expressing ChR2-YFP in vgat-IRES-Cre mice (Vh= −70mV; KCl-based pipette solution; three 5ms light pulses:
blue bars). Photo-evoked postsynaptic currents (average of 30 trials) recorded in control ACSF (Con), in bicuculline-methiodide (Bic, 10 µM), in DNQX
(20 nM) and DNQX + Bic. f Half-width of GABA-A-mediated and AMPA-mediated photo-evoked postsynaptic currents (30 trials, 3 neurons; mean± SEM
in red; p< 0.001unpaired t-test). g Photo-evoked (SuMVgat→DG) GABA-A-mediated (left) and AMPA-mediated (right) postsynaptic currents recorded
at different membrane potential (Cs-based pipette solutions) and h. I−V curves of the GABAA- (black circle) and AMPA- (white circle) postsynaptic
currents (mean± SEM, n= 4). i GABAA- (top trace) and AMPA- (bottom trace) postsynaptic currents evoked by photostimulation of SuMVglut2→DG
input in vglut2-IRES-Cre mice. j Onset delay of GABAA- and AMPA-mediated postsynaptic currents (black circle: vgat-IRES-Cre mice and white circle:
vglut2-IRES-Cre mice; mean± SEM in red; p= 0.002 paired t-test)
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was reduced. Based on our data, the loss of SuMNos1/Vglut2 neu-
rons may have been responsible for decreased REM theta power.
While the effect of inhibition may appear modest, it was
actually striking in relation to the effect of acute inhibition of
other components of the arousal system with increased NREM
sleep and fragmentation of wakefulness. Inhibition or destruction
of other accepted components of the ascending arousal system
such as the locus coeruleus, tuberomammillary histamine neu-
rons, midline thalamus, or lateral hypothalamic orexin neurons
has little or no effect of sleep wake18, 21, 35, 48–51 while stimulation
in some of these studies can show potent arousal responses52.
While it is tempting to conclude that the ascending arousal net-
work is highly redundant, it may instead indicate a speciﬁcity of
function for individual components of the arousal network and it
does not mean that these nodes are not playing an important role
in intact animals. For example, locus ceruleus acute activation
promotes wakefulness, but destruction of these neurons only
prevents wake maintenance in a novel environment, without
changing baseline sleep−wake51.
The role of grandicellular SuMvgat/vglut2 neurons remains to be
determined. They are apparently less involved than the SuMNos1
cells in the control of wakefulness, but given the extraordinary
density of SuMvgat/vlgut2 terminals on the proximal dendrites of
dentate granule cells42–53 in the supragranular layer, an effect on
temporal precision of “dentate gating” and perhaps mnemonic
processes appears likely. Furthermore, they may play a role in the
plastic changes in the dentate gyrus that occur after status epilepticus
and during epileptogenesis, as the SuM terminals sprout and take on
an aberrant distribution in the dentate gyrus in a rat pilocarpine
model of post-status epilepticus medial temporal lobe epilepsy53.
Based on the anatomical connectivity of the SuM, as well as
these physiological effects, our ﬁndings strongly suggest that the
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SuM is a key node in the ascending arousal network, but the
precise neuroanatomical pathway mediating these wake-
promoting effects is not yet proven. Overall, there are three
major groups of projections from the SuM: First, the most
appreciated output innervates components of the hippocampal
network including the recently described entorhinal-dentate-CA2
circuit54, the septal area and diagonal band, subiculum and
entorhinal cortex20, as well as the medial prefontal cortices19, 20.
Second, while not as evident in the Vertes20 study, there is sig-
niﬁcant topographic innervation of the cerebral cortex19. Finally,
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particularly in the lateral-most SuM, there are projections to the
upper brainstem and the more lateral basal forebrain components
of the arousal system23–25, 55. Thus, particularly to the lateral
SuM, there are strong reciprocal connections with upper brain-
stem and midbrain components of the arousal system56, includ-
ing the parabrachial complex, locus coeruleus, dorsal raphe and
laterodorsal tegmental nuclei20, 23–25, 34, 55, 57–60. Ascending
connections include basal forebrain GABAergic and cholinergic
neurons61, cell groups recently shown to mediate arousal and
suppress cortical slowing, respectively21, 22. Wakefulness seems
most likely due to activation of the second or third group of
projections, reliant on the wide distribution of SuM efferents in
the cortex and the basal forebrain, similar to those of the locus
ceruleus51. Notably, prolonged wake was always associated with
increased theta activity, so the activation of these pathways by
SuMvglut2 or SuMNos1/Vglut2 neurons may not be independent.
Consistent with this observation that there are both spatial
learning impairments32, 33 and amnesia16 after SuM inactivation
or lesions in animal models or humans, and, as with the locus
ceruleus, reciprocal connection of the SuM with medial prefrontal
regions that subserve volitionally directed attention and the
volitional maintenance of wakefulness19, 20, 23, 57. Our data taken
together with previous studies, is most consistent with SuMvglut2
neurons being the long-sought caudal hypothalamic node of the
arousal system, playing a role in wakefulness, as well as attention
and mnemonic processes.
Methods
Mice. We used adult male heterozygous Vglut2-IRES-Cre, Vgat-IRES-Cre, NOS1-
IRES-Cre, non-Cre-expressing littermates and adult male homozygous Vglut2lox/lox
mice (8–12 weeks, 20–25 g; total n= 58 in vivo and n= 8 in vitro), generated as
described elsewhere62–64 and obtained from the Lowell or Jackson Laboratories.
For Cre mouse lines, Cre-recombinase was targeted just distal to the stop codon of
the vgat or vglut2 genes, respectively, using an optimized internal ribosomal entry
sequence (IRES), with endogenous gene promoters therefore driving Cre-
recombinase expression via a bicistronic message62. NOS1-IRES-Cre mice were
generated by insertion of an internal ribosome entry site (IRES) along with Cre
recombinase into the 3′ untranslated region of Nos163. Vglut2 conditional
knockout mice have loxP sites ﬂanking the second exon of the Vglut2 gene
(Vglut2ﬂox/ﬂox)64. Each strain was originally derived from 129S mice or embryonic
stem cells, but were back-crossed with C57BL/6J mice for two or more generations.
All mice were bred and genotyped, before and after use, in-house and maintained
on a 12 h light−dark cycle with food and water ad libitum. Procedures met National
Institutes of Health and Guide for the Care and Use of Laboratory Animals
standards; all protocols were approved by the Beth Israel Deaconess Medical
Center IACUC.
Vectors. We used the pAAV-hSyn-DIO-hM3D-mCherry and pAAV-hSyn-DIO-
hM4D-mCherry plasmids (from Dr. Brian Roth, University of North Carolina) to
provide the Cre-dependent hM3Dq and hM4Di transgene, packaged by standard
triple transfection protocol to generate helper virus-free pseudotyped AAV2/10
virus. An AAV2/10 rep/cap plasmid provided AAV2 replicase and AAV10 capsid
functions, while adenoviral helper functions were supplied by the pHelper plasmid
(Stratagene, La Jolla, CA). Brieﬂy, AAV-293 cells were transfected via calcium
phosphate precipitation with 1.33 pmol of pHelper, and 1.15 pmol each of AAV2/
10 and an AAV vector plasmid (double-ﬂoxed or FLEXED conﬁguration45. The
cells were collected 72 h later and the pellets resuspended in DMEM, freeze-thawed
three times and centrifuged to produce a clariﬁed viral lysate. Vector stocks were
titered by rtPCR (Eppendorf Realplex), ranging from ~ 1 × 1012 to 1 × 1013 copies/
ml. The necessity for Cre-enablement for hM3Dq and hM4Di expression was
conﬁrmed in vitro using HEK293-Cre cells. These vectors are referred to as AAV-
hM3Dq and AAV-hM4Di. For experiments in vglut2ﬂox/ﬂox mice, we used an
AAV serotype 10 vector expressing Cre-recombinase fused to GFP (AAV-Cre; Dr
Caroline Bass, University at Buffalo).
Surgery. Mice were anesthetized with ketamine/xylazine (100/10 mg/kg i.p.) and
placed in a stereotaxic frame. To selectively transduce hM3Dq receptors in glu-
tamatergic or GABAergic neurons of the SuM (SuMvglut2 and SuMvgat, respec-
tively), we placed bilateral injections of AAV-hM3Dq or AAV-hM4Di (15−75 nl/
side into the caudal hypothalamus (coordinates: AP= −2.45 to −2.7 mm, L=± 0.4
to 0.5 mm, DV= −4.9 mm65) of Vgat-IRES-Cre and Vglut2-IRES-Cre mice. For
controls we injected AAV-hM3Dq and AAV-hM4Di in non-Cre-expressing lit-
termates, with no changes in sleep−wake physiology, nor transduction of hM3Dq
or hM4Di, as we have previously reported21, 66. To transduce hM3Dq only in
neurons with disrupted vglut2 expression, we mixed equal portions of AAV-Cre
and AAV-hM3Dq, injecting this as above into the SuM of vglut2lox/lox mice.
Microinjections were made using a compressed air delivery system67. After
injections, headsets were implanted, consisting of a six pin plug (Heilind Elec-
tronics, Inc., Willmington, MA) soldered to four EEG screws (Pinnacle Technol-
ogies, Lawrence, KS) and two silver pad electrodes, then secured with dental
cement. Electrodes were 1 mm rostral and lateral to Bregma, 2 mm caudal and
lateral to Bregma, with EMG electrodes over nuchal muscles. In some, a twisted-
pair electrode was placed in the dorsal hippocampus unilaterally, with contacts
either side of the dentate gyrus pyramidal cell layer (Plastics One, Wallingford,
CT). Mice were kept warm until normal activity resumed then housed singly
thereafter.
Sleep−wake recordings. Four to 6 weeks later, mice were placed in transparent
acrylic barrels in well-ventilated, light-tight and sound attenuating isolation
chambers on a 12 h light−dark cycle and at 22± 1 °C, with typical bedding material
and ad libitum food and water. Mice were connected to a commutator with a
preampliﬁer unit (8202SL, Pinnacle Technologies, Lawrence, KS), and habituated
for 72 h. Ampliﬁer units (8200-K1-SL) were connected to a recording computer
running Sirenia Acquisition (Pinnacle Technologies) acquiring EEG (one oblique
(frontal contralateral parietal) and one longitudinal (frontal parietal) derivation,
and bipolar nuchal EMG), sampled at 400 or 600 Hz, with a hardware high-pass
ﬁlter of 0.5 Hz, most with synchronized infrared video. CNO and vehicle were
given in random order in early experiments with large sites of vector transduction
(Fig. 1c−f), and no order effect was noted.
Histology. Prior to perfusion, mice received CNO (0.3 mg/kg, IP 10 AM) before
deep anesthesia with chloral hydrate (200 mg/kg) and transcardial perfusion (20 ml
saline then 100 ml of neutral phosphate-buffered formalin (4%, Fisher Scientiﬁc,
Pittsburgh, PA). Brains were removed, incubated in 20% sucrose at 4 °C for at least
48 h, then sectioned at 40 µm on a freezing microtome in three series. cFos and
DsRed immunohistochemical staining used a diaminobenzidine (DAB) reaction,
with sections incubated overnight with primary (1:20 K, cFos; 1:10 K DsRed) then
secondary antibodies for 2 h, ABC reagents (1:1000; Vector Laboratories) for
90 min, then a 0.06% solution of 3,3-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich), sometimes with 0.05% CoCl2 and 0.01% NiSO4 (NH4), in PBS plus 0.02%
H2O2 for about 5 min (based on observed reaction product). The rabbit polyclonal
Fos antibody was raised against synthetic human cFos (4−17) (Oncogene Sciences,
rabbit polyclonal cat#Ab5). Rabbit polyclonal antibody anti-mCherry was raised
against DsRed (Clontech cat#632496) with speciﬁcity indicated by the lack of
immunostaining in control mice. For secondary antibody immunohistochemical
controls, primary antibodies were omitted and the tissue showed no background
immunoreactivity. Secondary antibodies included donkey anti-rabbit alexa ﬂuor
546 (Invitrogen; 1:500) and donkey anti-rabbit biotinylated (Invitrogen; 1:500).
In situ hybridization revealed the distribution of SuM neurons co-expressing
markers of GABA and glutamate release42, 43, using a vgat-IRES-Cre mouse,
crossed with an L10 reporter line68, along with in situ hybridization for vglut2
RNA. Sections were incubated overnight with hybridization buffer containing
vglut2 probe at 52.5 °C (gift from Dr. Shigafumi Yokota, Shimane University,
Izumo, Japan; see Niu et al.,60 for sense controls), rinsed in standard saline citrate
(SSC) with 50% formamide after rinsing in Tris-buffered saline (TBS) pH 7.5.
Fig. 7 Activation of SuMNos1 neurons promotes wakefulness. a NOS1 immunohistochemisty (left, white scale bar 500 µm applies to all panels of a and b)
reveals a subpoplulation of SuM neurons that only rarely contain vgat, shown as gray-white neurons on the merged image (right). b NOS1
immunohistochemistry (left) in a vglut-Cre L10 reported mouse (center) showing that NOS1 neurons are a subset of vglut2 neurons, with no examples of
neurons with NOS immoreactivity that were not vglut2 positive (right, merge). c Cartoon showing AAVx-FLEX-hM3Dq-mCherry recombining in NOS1 Cre
expressing neurons. d Injection site showing DAB reaction product in neurons positive for mCherry, with black nuclear reaction product in cFos positive
neurons after CNO injection (black scale bar, bottom right, 500 µm). e, f Hypnograms from two mice after vehicle and CNO, shows a strong effect of NOS1
cellular activation on wakefulness, with g, h the CSA (0−100 Hz, black bar shows the dark period, short white bars represent 20min and are spaced 1 h
apart) from the areas shown in e and f by the blue and red boxes, respectively. i Pooled data from seven mice showing the percentage of wakefulness in 1 h
bins after injection (****p< 0.0001, **p= 0.0023, *p= 0.0248)
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After additional TBS rinses, sections were incubated for 30 min in 1% blocking
reagent (Roche, cat#11 096 176 001) then overnight in peroxidise conjugated
anti-digoxigenin antibody (1:500; Roche cat#11 207 733 910). Sections were rinsed
in TBS then reacted with 1:50 Tyramide signal ampliﬁcation ﬂuorsent kit (TSA
Plus-A-Cy3, Perkin Elmer cat#NEL744001KT) diluted in ampliﬁcation diluent
(30 min).
To determine neuronal size, one high power ﬁeld of the SuM, immediately
above the mammillothalamic tract before it emerges dorsally through the
mammillary capsule was use to compare the size of SuMvgat/vglut2 and SuMvglut2
neurons. Neurons with clear nuclei and unambiguously distinguishable from
adjacent neurons were included and measured through their long axis. Student’s t-
test was used for parametric two-tailed comparison.
Data analysis. Physiological Data Analysis was performed with Spike 2 (version
8.05, Cambridge Electronic Design, UK) using the Ratsleepauto script (version
2.02, Cambridge Electronic Design), with complete manual rescoring to correct any
errors. Compressed spectral arrays were created by use of the sonogram feature of
Spike 2 (settings 32768 points, Hanning window). Images of sonograms were
imported into FIJI (ImageJ 2.0.0, NIH) despeckled before transfer to Inkscape
(version 0.91) for ﬁgure creation. Spectral data for comparison of discrete spectral
bands was performed by ‘Ratsleepauto’ script with 1024 points per Hanning
window, saved as text and imported to Excel where 60 Hz artifact was removed by
interpolation of points from 59.5 to 60.5 Hz, and spectral values were added into
spectral bands (slow wave 0−2 Hz, delta 2−4 Hz, low theta (LTheta) 4−7 Hz, high
theta (HTheta) 7−13 Hz, beta 13−30 Hz, gamma 30−120 Hz). Statistical analysis
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Fig. 8 Inhibition of SuMNos1 does not cause somnolence, but reduces REM theta activity. a Cartoon showing AAV-FLEX-hM4Di-mCherry recombining in
Nos1 neurons that express Cre. b Conditional transduction of inhibitory hM4Di in Nos1-IRES-Cre mice (mCherry ﬂuorescence with DAPI counterstain;
scale bar 500 µm). c, d Hypnograms from two mice over 12 h after vehicle and CNO 0.9 mg/kg injected at ZT12 (7 PM, lights-off). Unlike inhibition of all
glutamate neurons (Fig. 4), the hypnograms appeared similar regardless of treatment. e, f CSA after vehicle and CNO from the periods shown by the blue
and red boxes, respectively, in c and d (0−100 Hz, black bar shows the dark period, short white bars represent 20min and are spaced 1 h apart). g, h There
is no change in the amount of wakefulness, NREM or REM sleep (separate two-way ANOVA, wake, REM, and NREM: F (2, 192)= 1.709, 0.8381, 2.04;
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used two-way repeated-measures ANOVA for analysis of spectral and sleep−wake
effects. Post hoc and multiple t-tests were corrected with Bonferroni’s method.
Student’s t-test was used when a single comparison was made, and was two-tailed
in all cases. Software used was Prism (5.0, 6.0 h, 6.0 g; GraphPad, La Jolla, CA).
For objective statistical analysis of injection sites, a series of 16.4 T MRI gradient
echo images of the C57 mouse brain were obtained69, resampled to 30 (lateral) by
30 (dorsoventral) by 120 (axial) micron voxels and rotated to match the our typical
plane of histological sections and sampling (Mango version 3.4, Research Imaging
Institute, University of Texas). Injection sites were plotted (MRICron70 (version 8/
4/2014), McCausland Center for Brain Imaging, University of South Carolina)—
when staining could not be decided between somatic and parenchymal were
included in the injection site. Binary image, continuous group voxel-based lesion-
symptom mapping analysis with 1000 permutations was then conducted (NPM
(version 6/1/2015) component of MRICron) to correlate the duration of
wakefulness with injection sites, with negative z-scores then used (given association
with increasing score) corresponding to a false discovery rate ≤ 1%, and plotted as
a color map on MRI sections, as is standardly used for lesion-symptom mapping in
human fMRI studies71.
Image processing and graphics. Light micrographs (Zeiss Axioplan 2 or Olympus
Slide Scanner) were adjusted with respect to color balance, background and con-
trast (FIJI, ImageJ 2.0.0 with BIOP VSI Reader Pluggin, NIH), rotated and cropped
(Gimp 2.8.14) and imported into Inkscape (version 0.91). Fluorescence images
(Zeiss Axioplan 2 or Olympus Slide Scanner) were recolored as magenta (vglut2
in situ) and green (vgat-L10-GFP reporter). Brightness and contrast were adjusted
for each channel to make regions outside of the brain tissue black, and apply
maximal brightness to the highest signal. For Fig. 5a images were combined and a
threshold function was applied to recolor as white regions that had high signal in
both green and magenta channels to enhance the visibility of clearly double-labeled
neurons, with the original combined images serving as a reference (FIJI, ImageJ
2.0.0, NIH). Images were rotated and cropped (Gimp 2.8.14), before being
imported into Inkscape (Inkscape v0.91).
In vitro experiments. vgat-IRES-Cre (n= 5) and vglut2-IRES-Cre (n= 8) mice
(8−12 weeks, 20−25 g) were used for in vitro electrophysiological recordings. Mice
were injected unilaterally in the SuM (bregma −2.55 mm; midline 0.4 mm; dorsal
surface 4.9 mm) with 75 nl of an adeno-associated viral (AAV) vector coding for
Cre-dependent channelrhodopsin-2 (ChR2) (AAV-Flex-ChR2(H134R)-YFP vector;
titer: 6 × 1012 genomic copies/ml; circuit mapping experiments) or with 75 nl of
AAV-hM4Di-mCherry or AAV-Flex-mCherry (in vitro CNO experiments). Four to
six weeks after AAV injections, we performed in vitro recordings with further
veriﬁcation of the injection site after recording by ﬂuorescent microscopy.
To prepare brain slices, mice were anesthetized with isoﬂurane (5% in O2) and
transcardially perfused with ice-cold ACSF (N-methyl-D-glucamine, NMDG-based
solution) containing (in mM): 100 NMDG-Cl, 2.5 KCl, 20 HEPES, 1.24 NaH2PO4,
30 NaHCO3, 25 glucose, 2 thiourea, 5 Na-ascorbate, 3 Na-pyruvate, 0.5 CaCl2, 10
MgSO4 (pH 7.3 when carbogenated with 95% O2 and 5% CO2). Brains were
quickly removed and cut in coronal slices (250 µm thick) using a vibrating
microtome (VT1200S, Leica, Bannockburn, IL, USA), then transferred into normal
ACSF (Na-based solution) containing (in mM): 120 NaCl, 2.5 KCl, 1.3 MgSO4, 10
glucose, 26 NaHCO3, 1.24 NaH2PO4, 2 thiourea, 1 Na-ascorbate, 3 Na-pyruvate, 4
CaCl2, (pH 7.4 when carbogenated with 95% O2 and 5% CO2, 310−320 mOsm).
For circuit mapping experiments, we recorded from granule cells in the dentate
gyrus of the dorsal hippocampus (bregma: −1.7 to −2.3 mm)65, targeted by use of
infrared differential interference contrast (IR-DIC) video microscopy and IR-
sensitive CCD camera (ORCA-ER, Hamamatsu, Bridgewater, NJ, USA). Whole-
cell recordings used a Multiclamp 700B ampliﬁer (Molecular Devices, Foster City,
CA, USA), a Digidata 1550 A interface and Clampex 10.6 software (Molecular
Devices). SuM axons and synaptic terminals expressing ChR2 were activated by a
full-ﬁeld 5 ms ﬂashes of light ( ~ 10 mW/mm2 1mm beam width) from a 5W
luxeon blue light-emitted diode (470 nm wavelength; #M470L2-C4; Thorlabs,
Newton, NJ, USA) coupled to the epiﬂuorescence pathway of the Zeiss microscope.
The area stimulated included the recorded cell, centered in a 500 µm radius
concentric ﬁeld. Photo-evoked postsynaptic currents were recorded using a KCl-
based pipette solution containing (in mM): 140 KCl, 1 EGTA, 10 HEPES, 1 MgCl2,
5 Mg-ATP, and 0.3 Na-GTP (pH adjusted to 7.2 with KOH, 280 mOsm) or a Cs-
based pipette solution containing (in mM): 125 CsMeS, 11 KCl, 10 HEPES, 0.1
CaCl2, 1 EGTA, 5 Mg-ATP, and 0.3 Na-GTP (pH adjusted to 7.2 with KOH,
280 mOsm). Electrophysiological data were analyzed using Clampﬁt 10.5
(Molecular Devices) and IGOR Pro 6 (WaveMetrics, Lake Oswego, OR, USA).
Synaptic events were detected off-line using Mini Analysis 6 (Synaptosoft, Leonia,
NJ, USA). The latency of the photo-evoked postsynaptic currents was determined
by the time difference between the starting of the light pulse and the 5% rise point
of the ﬁrst synaptic event72. Results are expressed as mean± SEM, n refers to
the number of cells. For the experiments with CNO we recorded SuMvglut2 neurons
expressing hM4Di-mcherry (transfected with the AAV-hM4Di-mCherry vector) or
only mCherry (transfected with the AAV-Flex-mCherry vector; control). Current-
clamp and cell attached recordings were made using K-Glu-based pipette solution
containing (in mM): 120 K-gluconate, 10 KCl, 3 MgCl2, 10 HEPES, 2.5 K-ATP, and
0.5 Na-GTP (pH adjusted to 7.2 with KOH, 280 mOsm). CNO was dissolved in
normal ACSF to ﬁnal concentration of 5 µM on the day of the experiment. All
drugs used in the in vitro experiments were purchased from Thermo Fisher
Scientiﬁc (Waltham, MA) with the exception of Bicuculline methiodide (Tocris,
Bristol, UK) and CNO (Sigma-Aldrich, St. Louis, MO).
Data availability. All data are available by contacting the corresponding author at
npeders@emory.edu.
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